[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-distress-syndrome-in-premature-infants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-distress-syndrome-in-premature-infants":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100619853","phase-4-calfactant-vs-poractant-alfa-using-a-less-invasive-technique-in-preterm-infants-with-respiratory-distress-syndrome-100619853",false,"NCT07350018","Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome","Comparison of the Efficacy of Calfactant and Poractant Alfa Surfactants Administered by a Less Invasive Surfactant Administration Technique in Preterm Infants With Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Born at a participating study center hospital.\n* Gestational age between 24 1\u002F7 and 29 6\u002F7 weeks (\\\u003C30 0\u002F7 weeks).\n* Postnatal age within the first 6 hours of life.\n* Being on non-invasive respiratory support.\n* Presence of clinical and radiological findings consistent with respiratory distress syndrome (RDS).\n* Indication for surfactant therapy defined as a requirement for FiO₂ \\>30% to achieve target oxygen saturation (SpO₂ 90-94%) while receiving noninvasive respiratory support with a minimum pressure of 6 cmH₂O.\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Infants who were intubated for any reason before the decision to administer surfactant.\n* Severe birth asphyxia, defined as the need for advanced resuscitation after birth, 10th minute Apgar score ≤5, and arterial blood gas within the first hour of life showing pH \\\u003C7.0 and base excess (BE) ≤-12.\n* Presence of major congenital anomalies.\n* Respiratory distress due to causes other than respiratory distress syndrome (RDS).\n* Congenital heart disease.\n* Congenital diaphragmatic hernia.\n* Pulmonary hypoplasia.\n* Chromosomal abnormalities.\n* Presence of pneumothorax.\n* Lack of informed consent.\n* Neonatal seizures presence.\n* Postnatal age greater than 6 hours.\n* Infants born outside of gestational weeks 24 1\u002F7 - 29 6\u002F7.\n* Requirement for invasive mechanical ventilation at enrollment.\n* Infants receiving noninvasive respiratory support with an FiO₂ requirement \\\u003C0.30.","ALL","0 Hours","6 Hours",{"count":20,"type":21},234,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Respiratory distress syndrome (RDS) is a common cause of respiratory failure in preterm infants and is frequently treated with surfactant therapy. With the increasing use of noninvasive ventilation, less invasive methods of surfactant administration have been developed. In the technique known as Less Invasive Surfactant Administration (LISA), surfactant is delivered into the trachea through a thin catheter, without the need for endotracheal intubation. This approach may reduce lung injury and improve respiratory outcomes in spontaneously breathing preterm infants. This multicenter, prospective, randomized study aims to compare the clinical effectiveness of poractant alfa and calfactant when administered using the LISA technique in preterm infants born at less than 30 weeks' gestation with RDS who are not intubated. The study will evaluate short-term outcomes, including the need for intubation, repeat surfactant administration, and respiratory support during the first 72 hours of life, as well as longer-term outcomes such as bronchopulmonary dysplasia and other neonatal morbidities.",[27,28,29],"Respiratory Distress Syndrome in Premature Infants","Respiratory Distress Syndrome (RDS)","Surfactant",[31,32,33,34,35,36,37],"Respiratory Distress Syndrome","Premature infant","Poractant alfa","Calfactant","surfactant treatment","Less Invasive Surfactant Administration","LISA","RECRUITING","2026-04-27",{"date":41,"type":42},"2026-04-28","ACTUAL",{"date":44,"type":42},"2026-01-20",{"date":46,"type":21},"2027-02-20",{"name":48,"class":49},"Uludag University","OTHER",5]